823
+4.18%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Koa Shoji Holdings Co
Its shares trade on Tokyo Stock Exchange under the ticker 9273.T. It has been listed since 21 June 2018. In the fiscal year to 30 June 2026, it reported revenue of ¥24.68bn and net income of ¥3.75bn. At that date it held total assets of ¥39.53bn and shareholders' equity of ¥31.18bn.
Koa Shoji Holdings Co., Ltd. engages in the manufacture, stock and sale of pharmaceutical ingredient and pharmaceuticals. The company is headquartered in Yokohama, Kanagawa-Ken. The company went IPO on 2018-06-21. The firm operates through two business segments. The pharmaceutical manufacturing and sales business is engaged in development, manufacturing, contract manufacturing and sales of generic injection, oral preparation and external preparation. The drug substance sales business is engaged in import and export of generic drug raw materials, as well as introducing and supply of pharmaceutical raw materials and preparations.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 21 Jun 2018
- Employees
- 297
- Website
- koashoji-hd.com ↗
Leadership
Pay as last reported
- Mr. Toshiyuki ShutoPresident, Chairman of Subsidiaries, Representative Director, since 2015
- Mr. Toshihiro HironoVice President, Director, since 2015
- Ms. Ritsuko OhtsukaVice President, Director, since 2015
- Mr. Toshinori KoyamaSenior Managing Director, since 2015
- Ms. Miyoko KomatsuManaging Director, since 2016
- Mr. Hiroki ToyodaExecutive Officer, Director of General Affairs
- Mr. Shinro SadanobuDirector
- Mr. Teruyuki TanakaDirector
- Ms. Kyoko HayashiIndependent Director
- Mr. Yoshitaka HiraoIndependent Director
- Mr. Hiroshi KinoshitaIndependent Director
- Mr. Yuki YamagishiIndependent Director, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Koa Shoji Holdings employs 297 full-time employees in Yokohama, Japan.
- The company operates two business segments in pharmaceutical manufacturing and drug substance sales.
- Koa Shoji Holdings went public on 21 June 2018, securing market access.
Weaknesses
- The company's pharmaceutical manufacturing segment focuses on generic injections and oral preparations only.
- Koa Shoji Holdings has no mention of international expansion beyond Japan.
- The firm's drug substance sales business relies on import and export activities.
Opportunities
- The pharmaceutical manufacturing segment can expand into new generic drug markets.
- Koa Shoji Holdings can leverage its drug substance sales for global raw material supply.
- The company may grow through contract manufacturing partnerships in Japan.
Threats
- The pharmaceutical industry faces regulatory challenges in Japan.
- Koa Shoji Holdings' reliance on generic drug manufacturing exposes it to market saturation.
- Competition in the drug substance sales business could increase costs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.